MINOGUE MICHAEL R 4: 2,030 shares of PODD ($499,846)

Our Take

→Michael Minogue's half-million-dollar purchase of Insulet stock is noteworthy for its size and timing: as Chief Commercial Officer, he's betting heavily on the company's ability to execute its international expansion strategy, particularly in Europe and Asia-Pacific markets where adoption of automated insulin delivery remains underpenetrated compared to the U.S. This move signals confidence that Insulet's margins and revenue growth can sustain through what has historically been a volatile execution phase for medtech companies scaling internationally.